SubsidieMeestersCustom-Made Designer Macrophages to Revolutionize the Safety of Parenteral Drugs
iPYRO aims to revolutionize drug safety evaluations by developing a standardized, economically produced macrophage-based cell product from iPSC, ensuring regulatory compliance and industry readiness.
Projectdetails
Introduction
The iPYRO proposal is built upon the uniqueness of human induced pluripotent stem cells (iPSC) and recent innovations in the farming of fully defined human macrophages (iMonoMac) using industry-compatible bioreactors.
Industry Need
Given the growing need for industrial macrophages, iPYRO sets an innovation in the forefront of drug safety evaluations, supplying a unique cell type that meets the expectations from industry and regulators.
Breakthrough Innovation
The breakthrough innovation of iPYRO will offer a superior, thus highly standardized, economically produced, and fully validated off-the-shelf macrophage-based cell product to revolutionize the safety of drugs and beyond.
Regulatory Compliance and Business Strategy
To maximize the outcome, iPYRO will assess the regulatory compliance while further streamlining the iMonoMac product for the envisioned spinout. This includes:
- Establishing a proper freedom-to-operate strategy
- Developing a suitable business model
Transition from Academia to Industry
The seminal iMonoMac platform, along with the unique IPR and established contacts to industrial and regulatory stakeholders, will pave the transition from academia to industry. This initiative will introduce, for the very first time, an iPSC-cell product for the drug safety market.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-1-2023 |
| Einddatum | 30-6-2024 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- MEDIZINISCHE HOCHSCHULE HANNOVERpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Moving cell-based immunotherapies to fight bacterial lung infections into the clinicsiMAClung aims to develop an immune cell-based therapy using induced pluripotent stem cell-derived macrophages to combat bacterial airway infections and enhance lung regeneration. | ERC Proof of... | € 150.000 | 2024 | Details |
Scaling up iPSC Expansion and Differentiation using Recombinant BioemulsionsThe project aims to develop scalable, regulatory-compliant bioemulsions using engineered protein nanosheets for efficient iPSC culture and differentiation, enhancing cell manufacturing and biotech market growth. | ERC Proof of... | € 150.000 | 2025 | Details |
Novel macrodiolide ImmunosuppressantsThis project aims to develop novel macrocyclic immunosuppressants targeting IRF3 to address autoimmune and neuroinflammatory disorders, while securing IP and preparing for future investment. | ERC Proof of... | € 150.000 | 2025 | Details |
Supramolecular microcapsules for bioreactor expansion of induced pluripotent stem cellsThe SUPROTECT project aims to develop squaramide-based microcapsules for culturing pluripotent stem cells, evaluating their effectiveness while securing intellectual property for potential licensing. | ERC Proof of... | € 150.000 | 2024 | Details |
Allogeneic Macrophages for Cancer TherapyONCOMAC aims to prepare a preclinical proof-of-concept study for genetically engineered human macrophages as a novel cancer cell therapy, ensuring compliance with regulatory standards for clinical trials. | ERC Proof of... | € 150.000 | 2022 | Details |
Moving cell-based immunotherapies to fight bacterial lung infections into the clinics
iMAClung aims to develop an immune cell-based therapy using induced pluripotent stem cell-derived macrophages to combat bacterial airway infections and enhance lung regeneration.
Scaling up iPSC Expansion and Differentiation using Recombinant Bioemulsions
The project aims to develop scalable, regulatory-compliant bioemulsions using engineered protein nanosheets for efficient iPSC culture and differentiation, enhancing cell manufacturing and biotech market growth.
Novel macrodiolide Immunosuppressants
This project aims to develop novel macrocyclic immunosuppressants targeting IRF3 to address autoimmune and neuroinflammatory disorders, while securing IP and preparing for future investment.
Supramolecular microcapsules for bioreactor expansion of induced pluripotent stem cells
The SUPROTECT project aims to develop squaramide-based microcapsules for culturing pluripotent stem cells, evaluating their effectiveness while securing intellectual property for potential licensing.
Allogeneic Macrophages for Cancer Therapy
ONCOMAC aims to prepare a preclinical proof-of-concept study for genetically engineered human macrophages as a novel cancer cell therapy, ensuring compliance with regulatory standards for clinical trials.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
AI-powered platform for autologous iPSC manufacturingThe project aims to develop an AI-guided microfluidic device for the standardized, cost-effective mass production of personalized iPSCs to enhance cancer therapies and tissue regeneration. | EIC Pathfinder | € 3.999.225 | 2022 | Details |
Hyper-targeting CAR NK cells from induced pluripotent stem cells for novel off-the-shelf anti-tumor therapiesThe HyperTargIPS-NK project aims to develop a scalable, off-the-shelf NK cell therapy using iPS cells to target and treat lethal cancers like pancreatic cancer, glioblastoma, and AML. | EIC Pathfinder | € 3.798.713 | 2023 | Details |
Precision control of glycosylation to open a new era of therapeutic antibodiesGlycoBoost aims to revolutionize monoclonal antibody design by producing therapeutics with uniform N-glycans, enhancing safety and efficacy for autoimmune disease treatments. | EIC Transition | € 2.499.540 | 2025 | Details |
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug developmentCherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing. | EIC Accelerator | € 2.499.831 | 2024 | Details |
NOn-VIral gene modified STEM cell therapyThis project aims to develop a high-throughput protocol for producing gene-corrected CAR T cells and blood stem cells using optimized photoporation and CRISPR technology for enhanced clinical application. | EIC Pathfinder | € 3.644.418 | 2022 | Details |
AI-powered platform for autologous iPSC manufacturing
The project aims to develop an AI-guided microfluidic device for the standardized, cost-effective mass production of personalized iPSCs to enhance cancer therapies and tissue regeneration.
Hyper-targeting CAR NK cells from induced pluripotent stem cells for novel off-the-shelf anti-tumor therapies
The HyperTargIPS-NK project aims to develop a scalable, off-the-shelf NK cell therapy using iPS cells to target and treat lethal cancers like pancreatic cancer, glioblastoma, and AML.
Precision control of glycosylation to open a new era of therapeutic antibodies
GlycoBoost aims to revolutionize monoclonal antibody design by producing therapeutics with uniform N-glycans, enhancing safety and efficacy for autoimmune disease treatments.
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development
Cherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing.
NOn-VIral gene modified STEM cell therapy
This project aims to develop a high-throughput protocol for producing gene-corrected CAR T cells and blood stem cells using optimized photoporation and CRISPR technology for enhanced clinical application.